@article{ref1,
title="Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study",
journal="Human psychopharmacology",
year="2011",
author="Kim, Jae-Min and Kim, Sung-Wan and Stewart, Robert and Kim, Seon-Young and Yoon, Jin-Sang and Jung, Sung-Won and Lee, Min-Soo and Yim, Hyeon-Woo and Jun, Tae-Youn",
volume="26",
number="1",
pages="41-50",
abstract="OBJECTIVE: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. METHODS: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. RESULTS: For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. CONCLUSIONS: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and a previous suicide attempt were markers of worse outcome. Copyright © 2011 John Wiley & Sons, Ltd.<p /> <p>Language: en</p>",
language="en",
issn="0885-6222",
doi="10.1002/hup.1168",
url="http://dx.doi.org/10.1002/hup.1168"
}